Skip to main content
Erschienen in: Strahlentherapie und Onkologie 11/2015

01.11.2015 | Original Article

Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma

verfasst von: Doo Yeul Lee, M.D., Joong-Won Park, M.D., Tae Hyun Kim, M.D., Ju Hee Lee, M.D., Bo Hyun Kim, M.D., Sang Myung Woo, M.D., Sang Soo Kim, Ph.D., Woo Jin Lee, M.D., Dae Yong Kim, M.D., Chang-Min Kim, M.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To identify prognostic indicators in patients treated with radiotherapy (RT) for metastases from hepatocellular carcinoma (HCC) in abdominal lymph nodes (LNs).

Patients and methods

RT was used to treat 65 patients for metastases from HCC in abdominal LNs. Total radiation dose was 30–60 Gy (median 52.8 Gy), with fraction size 1.8–3 Gy. RT was administered five times per week to an equivalent dose in 2-Gy fractions (EQD2; Gy10) of 32.5–65 Gy10 (median 54 Gy10) and an α/βratio for tumor and acute effects of normal tissue of 10.

Results

Median overall survival (OS) in all patients was 8.1 months. LN responders had significantly higher median OS than nonresponders (14.5 vs. 3.7 months, p < 0.05). Multivariate analysis showed that Child-Pugh classification, status of intrahepatic tumor, number of metastatic LNs, and LN response were independently predictive of OS (p < 0.05 each). Based on results of multivariate analysis, patients were prognostically stratified according to pretreatment risk factors, including Child-Pugh classification, intrahepatic tumor status, and number of metastatic LNs; with the expected median OS in patients with ≥ 2, 1, and 0 risk factors being 2.9, 9.8, and 27.6 months, respectively (p < 0.05).

Conclusion

Our data showed that LN response to RT was an independent prognostic factor for OS in advanced HCC patients with abdominal LN metastases, and suggested that RT for metastatic LNs might improve OS in these patients. In addition, our data suggest that Child-Pugh classification, intrahepatic tumor status, and number of metastatic LNs may be useful prognostic and therapeutic indicators for selecting treatment strategies.
Literatur
1.
Zurück zum Zitat Ercolani G, Grazi GL, Ravaioli M et al (2004) The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg 239:202–209PubMedCentralCrossRefPubMed Ercolani G, Grazi GL, Ravaioli M et al (2004) The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg 239:202–209PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Sun HC, Zhuang PY, Qin LX et al (2007) Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol 96:37–45CrossRefPubMed Sun HC, Zhuang PY, Qin LX et al (2007) Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol 96:37–45CrossRefPubMed
3.
Zurück zum Zitat Xiaohong S, Huikai L, Feng W, Ti Z, Yunlong C, Qiang L (2010) Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma. World J Surg 34:1028–1033CrossRefPubMed Xiaohong S, Huikai L, Feng W, Ti Z, Yunlong C, Qiang L (2010) Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma. World J Surg 34:1028–1033CrossRefPubMed
4.
Zurück zum Zitat Watanabe J, Nakashima O, Kojiro M (1994) Clinicopathologic study on lymph node metastasis of hepatocellular carcinoma: a retrospective study of 660 consecutive autopsy cases. Jpn J Clin Oncol 24:37–41PubMed Watanabe J, Nakashima O, Kojiro M (1994) Clinicopathologic study on lymph node metastasis of hepatocellular carcinoma: a retrospective study of 660 consecutive autopsy cases. Jpn J Clin Oncol 24:37–41PubMed
5.
Zurück zum Zitat Liver Cancer Study Group of J (1990) Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 211:277–287 Liver Cancer Study Group of J (1990) Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 211:277–287
6.
Zurück zum Zitat Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL (2000) Extrahepatic metastases of hepatocellular carcinoma. Radiology 216:698–703CrossRefPubMed Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL (2000) Extrahepatic metastases of hepatocellular carcinoma. Radiology 216:698–703CrossRefPubMed
7.
Zurück zum Zitat Uchino K, Tateishi R, Shiina S et al (2011) Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 117:4475–4483CrossRefPubMed Uchino K, Tateishi R, Shiina S et al (2011) Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 117:4475–4483CrossRefPubMed
8.
Zurück zum Zitat Park YJ, Lim do H, Paik SW et al (2006) Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol 41:1099–1106CrossRefPubMed Park YJ, Lim do H, Paik SW et al (2006) Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol 41:1099–1106CrossRefPubMed
9.
Zurück zum Zitat Zeng ZC, Tang ZY, Yang BH et al (2004) Radiation therapy for the locoregional lymph node metastases from hepatocellular carcinoma, phase I clinical trial. Hepatogastroenterology 51:201–207PubMed Zeng ZC, Tang ZY, Yang BH et al (2004) Radiation therapy for the locoregional lymph node metastases from hepatocellular carcinoma, phase I clinical trial. Hepatogastroenterology 51:201–207PubMed
10.
Zurück zum Zitat Zeng ZC, Tang ZY, Fan J et al (2005) Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys 63:1067–1076CrossRefPubMed Zeng ZC, Tang ZY, Fan J et al (2005) Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys 63:1067–1076CrossRefPubMed
11.
Zurück zum Zitat Yamashita H, Nakagawa K, Shiraishi K et al (2007) Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: retrospective study. J Gastroenterol Hepatol 22:523–527CrossRefPubMed Yamashita H, Nakagawa K, Shiraishi K et al (2007) Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: retrospective study. J Gastroenterol Hepatol 22:523–527CrossRefPubMed
12.
13.
Zurück zum Zitat Kim K, Chie EK, Kim W et al (2010) Absence of symptom and intact liver function are positive prognosticators for patients undergoing radiotherapy for lymph node metastasis from hepatocellular carcinoma. Int J Radia Oncol Biol Phys 78:729–734CrossRef Kim K, Chie EK, Kim W et al (2010) Absence of symptom and intact liver function are positive prognosticators for patients undergoing radiotherapy for lymph node metastasis from hepatocellular carcinoma. Int J Radia Oncol Biol Phys 78:729–734CrossRef
14.
Zurück zum Zitat Chen YX, Zeng ZC, Fan J et al (2013) Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases. Clin Transl Oncol 15:732–740CrossRefPubMed Chen YX, Zeng ZC, Fan J et al (2013) Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases. Clin Transl Oncol 15:732–740CrossRefPubMed
15.
Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed
16.
Zurück zum Zitat Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34CrossRefPubMed Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34CrossRefPubMed
17.
Zurück zum Zitat Korean Liver Cancer Study Group and National Cancer Center Korea (2009) [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol 15:391–423CrossRef Korean Liver Cancer Study Group and National Cancer Center Korea (2009) [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol 15:391–423CrossRef
18.
Zurück zum Zitat Fowler JF (1989) The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:679–694CrossRefPubMed Fowler JF (1989) The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:679–694CrossRefPubMed
19.
Zurück zum Zitat Kim TH, Park JW, Kim YJ et al (2014) Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther Onkol 190:882–890CrossRefPubMed Kim TH, Park JW, Kim YJ et al (2014) Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther Onkol 190:882–890CrossRefPubMed
20.
Zurück zum Zitat Lee SU, Park JW, Kim TH et al (2014) Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol 190:806–814CrossRefPubMed Lee SU, Park JW, Kim TH et al (2014) Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol 190:806–814CrossRefPubMed
21.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
22.
Zurück zum Zitat Sugahara S, Nakayama H, Fukuda K et al (2009) Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 185:782–788CrossRefPubMed Sugahara S, Nakayama H, Fukuda K et al (2009) Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 185:782–788CrossRefPubMed
23.
Zurück zum Zitat Lee JH, Kim DH, Ki YK et al (2014) Three-dimensional conformal radiotherapy for portal vein tumor thrombosis alone in advanced hepatocellular carcinoma. Radiat Oncol J 32:170–178PubMedCentralCrossRefPubMed Lee JH, Kim DH, Ki YK et al (2014) Three-dimensional conformal radiotherapy for portal vein tumor thrombosis alone in advanced hepatocellular carcinoma. Radiat Oncol J 32:170–178PubMedCentralCrossRefPubMed
24.
Zurück zum Zitat Kim TH, Park JW, Kim YJ et al (2015) Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat 47:34–45PubMedCentralCrossRefPubMed Kim TH, Park JW, Kim YJ et al (2015) Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat 47:34–45PubMedCentralCrossRefPubMed
25.
Zurück zum Zitat A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998 Sep;28(3):751-755 A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998 Sep;28(3):751-755
26.
Zurück zum Zitat Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338CrossRefPubMed Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338CrossRefPubMed
27.
Zurück zum Zitat Nanashima A, Sumida Y, Abo T et al (2006) Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol 41:250–256CrossRefPubMed Nanashima A, Sumida Y, Abo T et al (2006) Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol 41:250–256CrossRefPubMed
28.
Zurück zum Zitat Kobayashi S, Takahashi S, Kato Y et al (2011) Surgical treatment of lymph node metastases from hepatocellular carcinoma. J Hepatobiliary-Pancreat Sci 18:559–566CrossRefPubMed Kobayashi S, Takahashi S, Kato Y et al (2011) Surgical treatment of lymph node metastases from hepatocellular carcinoma. J Hepatobiliary-Pancreat Sci 18:559–566CrossRefPubMed
Metadaten
Titel
Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma
verfasst von
Doo Yeul Lee, M.D.
Joong-Won Park, M.D.
Tae Hyun Kim, M.D.
Ju Hee Lee, M.D.
Bo Hyun Kim, M.D.
Sang Myung Woo, M.D.
Sang Soo Kim, Ph.D.
Woo Jin Lee, M.D.
Dae Yong Kim, M.D.
Chang-Min Kim, M.D.
Publikationsdatum
01.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 11/2015
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0873-8

Weitere Artikel der Ausgabe 11/2015

Strahlentherapie und Onkologie 11/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.